PITTSBURGH–August 11, 2017 - Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, today announced the appointment of Mark Collins, Ph.D. as Vice President of Innovation and Strategy. Dr. Collins will be joining Helomics to drive the development of Helomics’ proprietary bioinformatics platform D-CHIP™ (Dynamic Clinical Health Insight Platform) and the utilization of the platform across all of Helomics’ business sectors.
Dr. Collins has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.
Dr. Mark Collins stated, “I am passionate about the value of bioinformatics to the search for new precision therapies. Helomics represents a unique opportunity to pursue that passion, combining precision cancer diagnostics and a CLIA certified lab together with a pipeline of innovation from collaborations with local universities and our new life science incubator. I am delighted to be joining Helomics to drive the development of the D-CHIP™ knowledgebase platform, which will provide a rich source of clinical and molecular insights on patients with cancer. I firmly believe that this knowledge-driven approach will allow our Pharma customers to advance precision medicine, drive biomarker research, and design and run better clinical trials.”
“I am very pleased to have Dr. Mark Collins join the senior management team at Helomics.” stated Gerald J. Vardzel Jr., President and CEO of Helomics. “Mark is an innovative, strategic thinker and brings significant bioinformatics and business experience to Helomics. His expertise will be invaluable as we continue to develop and commercialize D-CHIP™, our proprietary bioinformatics platform for multi-omic tumor biochemical data and patient demographic information.”
“I am looking forward to working with Mark on a number of new scientific strategic initiatives,” stated Dr. Don Very, Vice President of Scientific Strategy, Commercialization and Research at Helomics. “Mark’s bioinformatics expertise will allow us to fully leverage the clinical utility of the multi-omic biochemical and genetic information derived from our Comprehensive Tumor Profiling platform. Additionally, his pharmaceutical and commercial experience will be extremely useful in positioning our core scientific and clinical CRO offerings to potential partner-clients in the pharmaceutical and diagnostic industries.”
About Helomics Corporation
Helomics is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Helomics offers advanced clinical laboratory diagnostic tests as well as, partnering with Pharma, BioPharma and diagnostics companies via its integrated clinical CRO services to provide customized solutions for research, development and commercialization of new therapies to provide a customized solution to our client’s specific product development needs. Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information please visit: www.helomics.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
For more information regarding Helomics Corporation, please contact:
Sources: Helomics® Corporation